DILI: Clinical Trials and Post-Marketing

This course is led by a Hepatologist with extensive experience in clinical assessment of DILI and who published ‘RUCAM’ the widely used causality assessment method of DILI.

返回 Agenda

SESSION 5: INDIVIDUAL DATA, HY’S LAW AND AGGREGATED DATA

Session Chair(s)

Gaby L. Danan, MD, PHD

Pharmacovigilance Expert

GLD, France

Data elements to collect
HY’S Law: Definition and conditions for use
Case studies
Data analysis principles

Speaker(s)

INDIVIDUAL DATA, HY’S LAW AND AGGREGATED DATA

Gaby L. Danan, MD, PHD

GLD, France

Pharmacovigilance Expert

DILI: Clinical Trials and Post-Marketing

SESSION 5: INDIVIDUAL DATA, HY’S LAW AND AGGREGATED DATA

Session Chair(s)

Gaby L. Danan, MD, PHD

Speaker(s)

INDIVIDUAL DATA, HY’S LAW AND AGGREGATED DATA

获得信息并保持参与